H.C. Wainwright Initiates Coverage on vTv Therapeutics Inc(NASDAQ:VTVT). The shares have been rated Buy. The rating by H.C. Wainwright was issued on Sep 26, 2016.
vTv Therapeutics Inc(VTVT) last announced its earnings results on Aug 2, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $182.00K. Analysts had an estimated revenue of $100.00K. Earnings per share were $-0.47. Analysts had estimated an EPS of $-0.85.
Several Insider Transactions has been reported to the SEC. On Feb 5, 2016, Ronald O Perelman (10% owner) purchased 10,000 shares at $6.43 per share price.Also, On Dec 16, 2015, Noel Joseph Spiegel (director) purchased 5,710 shares at $6.20 per share price.On Sep 28, 2015, Paul G Savas (director) purchased 5,000 shares at $6.62 per share price, according to the Form-4 filing with the securities and exchange commission.
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. The Company provides a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a range of human diseases including central nervous system disorders metabolic disorders inflammation and cancer. The Company provides programs for the treatment of Alzheimers disease (AD) and type II diabetes. Its lead candidate is Azeliragon (TTP488) and its type II diabetes drug candidates include Glucokinase Activator (TTP399) and GLP-1r Agonist (TTP273). The Company also offers products for the prevention of muscle weakness and the treatment of inflammatory disorders which include HPP593 HPP737 and HPP971. The Company utilizes TTP Translational Technology to discover small molecule therapeutics for diseases and to validate biological pathways and targets.